NRI

West and East Lealman, FL, United States
West and East Lealman, FL, United States
SEARCH FILTERS
Time filter
Source Type

TOKYO--(BUSINESS WIRE)--Nomura Research Institute, Ltd. (NRI), a leading provider of consulting services and system solutions, in collaboration with Mizuho Bank, Ltd., today announced the completion of a proof-of-concept (PoC) project developed to examine the applications of artificial intelligence (AI) solutions for derivative contract operation. Mizuho executives made the improvement of the operational efficiency of derivative contract procedures a priority and approached NRI to develop a test in which the bank could examine how AI solutions could address this need. Traditionally, the standard derivative contract procedure at Mizuho included the exchange of print ISDA contracts with clients via FAX and PDF and the manual archiving of all the information. As each contract contains an enormous amount of information that is unique to each individual contract, registering the information to the system and referring to past contracts requires not only specialized knowledge but also a large amount of time-consuming manual input. The PoC confirmed that OCR (Optical Character Recognition) can digitize ISDA contracts and the system can define, extract, and archive the sum total of information from the digitized contract into a format that can be easily accessed and searched after the fact. As a result, the time it takes for analysts to register ISDA contract information into the system and refer to past information is significantly decreased. “We are excited to continue to develop new AI applications for functions across the financial industry with partners like Mizuho,” said Hiroyuki Nakayama, General Manager of Financial Business Planning Division of NRI. “NRI is at the forefront of AI research and development for the financial services sector in Asia, and we continue to learn new and exciting applications for the technology that we are seeking to implement further through strong partnerships.” Masahiro Ueki, Senior Vice President of Legal and Compliance Team and Global Markets Coordination Department at Mizuho said, “In addition to the improved operation efficiency brought by the AI implementation, we expect these exciting new systems can also maintain a high-level understanding of ISDA contract operations across the board.” Based on the PoC results, Mizuho intends to continue working with NRI to develop a full-fledged system solution for all derivative contract operations. NRI has been researching and conducting PoC for AI applications in document management, including contracts and payment record processing. NRI recently evaluated the iManage RAVN AI platform to automatically extract data from thousands of ISDA contracts. iManage automates routine cognitive tasks, provides powerful insights and streamlines how professionals work, while maintaining the highest level of security and governance over critical client and corporate data. Founded in 1965, NRI is a leading global provider of system solutions and consulting services with annual sales exceeding $3.7 billion. NRI offers clients holistic support of all aspects of operations from back- to front-office, with NRI’s research expertise and innovative solutions as well as understanding of operational challenges faced by financial services firms. The clients include broker-dealers, asset managers, banks and insurance providers. NRI has its offices globally including New York, London, Tokyo, Hong Kong and Singapore, with over 12,000 employees. Mizuho Bank, Ltd. is a financial institution registered with the Director of Kanto Local Finance Bureau (Tokin) No.6, and a member of Japan Securities Dealers Association, The Financial Futures Association of Japan and Type II Financial Instruments Firms Association. iManage transforms how professionals in legal, accounting and financial services get work done by combining the power of artificial intelligence with market leading content and email management. iManage automates routine cognitive tasks, provides powerful insights and streamlines how professionals work, while maintaining the highest level of security and governance over critical client and corporate data. Over one million professionals at over 3,000 organizations over 65 countries – including more than 2,000 law firms and 500 corporate legal departments – rely on iManage to deliver great client work. RAVN Systems was acquired by iManage on the 24th May 2017. The combined company will transform content management and accelerate the adoption of AI.


The website and the mobile app have an intuitive design that guides users to complete money transfer quickly. NRIs can now enjoy the convenience of a simplified transaction flow to transfer money to India in 3 simple clicks for their frequent transactions*. It provides an option of biometric authentication for logging into the mobile app as well as view the status of the transaction. They can also make quick payments for services in India to over 100 entities from the M2I website. They can do so for services including telephone bills, insurance premiums, and prepaid mobile recharge among others. The new responsive design also offers a coherent experience across multiple devices like desktops, mobiles and tablets. Frequent users of Money2India will be enabled for instant money transfer credit to their recipients in India. As an industry first, the bank has integrated its M2I website with its Internet banking platform. With this, NRIs can now access their bank accounts, transaction details as well as undertake remittances from a single Internet banking platform. This gives improved convenience to NRI customers as they are not required to separately login and authenticate themselves to access the M2I website. Ms. Chanda Kochhar, MD & CEO, ICICI Bank Ltd said, "ICICI Bank has pioneered and popularised many innovative solutions in the banking industry in India. It has always been our endeavour to provide world-class services to our customers. The new Money2India platform is yet another testimony to that effort. We see large number of our customers today transacting through our digital channels. The Money2India website and mobile app have been significantly enhanced to provide ease of sending money to India. It allows registered NRI customers to transfer money to India in just 3 clicks if it is frequently transferred. They also have an option to pay over 100 entities in India from the M2I website. We believe that these developments will offer a seamless user experience for NRIs looking to transfer money to India." NRIs, who are customers of any bank globally, can use the M2I website and mobile app to transfer money to any bank in India. New users can initiate a money transfer instantly with the help of a simple one-time registration. The simple transaction flow makes it easy even for a first time user to transact. Some of the key highlights of the website and application are: ICICI Bank Ltd is a pioneer and the largest player/bank in the remittances market in the country. Its 'Money2India' platform has been facilitating remittances into the country since the last 15 years, catering to over 1.5 million NRIs worldwide. In 2015, it also launched 'Money2World' India's first fully online service to transfer money from any bank in India to any bank overseas. The Bank also has a wide array of arrangement with a host of correspondent banks across the globe to enable quick and easy trans-border money transfers. For news and updates, visit http://www.money2india.com and follow us on Twitter at http://www.twitter.com/ICICIBank ICICI Bank Ltd (NYSE: IBN) is India's largest private sector bank by consolidated assets. The Bank's consolidated total assets stood at US$ 152.0 billion at March 31, 2017. ICICI Bank's subsidiaries include India's leading private sector insurance, asset management, securities brokerage and primary dealership companies, and among the country's largest private equity firms. It is present across 17 countries, including India. ICICI Bank Limited ("ICICI Bank") is incorporated in India and regulated by the Reserve Bank of India ("RBI") and maintains its corporate office in Mumbai, India. The products and services provided by ICICI Bank are subject to product/service specific terms & conditions. Please familiarize yourself with the terms and conditions applicable, available at http://www.icicibank.com and http://www.money2india.com. The products and services are also subject to RBI rules/regulations, prevailing foreign exchange regulations & other applicable Laws. ICICI Bank reserves the right to modify/change all or any of the terms and conditions governing the products and services. ICICI Bank also reserves the right to discontinue the products and services without assigning any reasons whatsoever. Any references to timelines or service levels are only indicative and should not be construed to refer to any commitment by us or any other service provider. The information contained in this document is not intended to nor should it be construed to represent that ICICI Bank provides any products or services in any jurisdiction where it is not licensed or registered or authorised to do so. The information provided herein is not intended nor should it be construed to represent that ICICI Bank is soliciting. The information provided herein is not intended for distribution to, or use by, any person in any jurisdiction where such distribution or use would be contrary to law or regulation. ICICI Bank and the "I man" logo are the trademarks and property of ICICI Bank. Canada: The overseas products and services are not the products and services of ICICI Bank Canada. The products and services are not eligible for or covered by deposit insurance of the Canada Deposit Insurance Corporation ("CDIC").


TOKYO--(BUSINESS WIRE)--Nomura Research Institute, Ltd. (NRI, TOKYO:4307), a leading provider of consulting services and system solutions, today announced that its back-office solution for asset management firms and trust banks, T-STAR/TX, will add service for Japan-domiciled foreign-denominated funds beginning in July 2017. The newly added service will assist asset managers with accounting and reporting. Japanese financial institutions, especially banks, have been investing heavily in securities in recent years. In particular, they have had a keen interest in investing in funds that hold foreign-currency asset. Currently, if a financial institution wants to invest foreign-currency holdings without converting them into yen, they have to purchase a foreign-domiciled fund denominated in the foreign currency. However, nearly all Japan-domiciled funds, including those that invest predominately in foreign-denominated assets, use the yen as their base currency. As a result, interest in Japan-domiciled foreign-denominated funds has increased due to the benefits it brings and the need for a domestically domiciled foreign-denominated investment trust. One of the benefits of Japan-domiciled foreign-denominated funds is tax advantage. A Japan-domiciled fund may be subject to a lower dividend tax rate than a foreign-domiciled fund, depending on the dividends’ source country. The second benefit is that information used for risk management can be more quickly obtained from Japan-domiciled funds than from foreign funds. Thirdly, Japan-domiciled funds can be created faster than foreign funds. By using the new service added to NRI’s T-STAR/TX solution, asset managers can manage attributions of foreign funds and calculate net asset value in the same way for Japan-domiciled funds. In addition, for privately placed investment trusts (both unit type and open investment trusts), asset managers can use the solution for trust property management, accounting, legal report creation, Bank for International Settlements (BIS) reporting, and digital communication of fund look-through data. They can also use the Business Process Outsourcing (BPO) service provided by NRI Process Innovation. Katsuhiko Fujita, Senior Managing Director of NRI, commented, “NRI is continually looking to expand our service offering to meet the needs of the changing marketplace, and the addition of our Japan-domiciled funds service to TSTAR/TX, is a testament to that. We are happy to continue to provide the most support for our asset management clients to give them a full service offering for better accounting and reporting.” The additional service is also in response to the Asia Region Fund Passport (ARFP)*1, which is expected to be launched by the end of 2017. With these industry changes in mind, NRI plans to continuously expand the functionality of T-STAR/TX to better serve asset managers. Founded in 1965, NRI is a leading global provider of system solutions and consulting services with annual sales above $3.7 billion. NRI offers clients holistic support of all aspects of operations from back- to front-office, with NRI’s research expertise and innovative solutions as well as understanding of operational challenges faced by financial services firms. The clients include broker-dealers, asset managers, banks and insurance providers. NRI has 35 offices globally including New York, London, Tokyo, Hong Kong and Singapore, and over 10,000 employees.


SANS Security Awareness provides organizations with a comprehensive solution that enables them to easily and effectively manage their human cyber security risk. SANS Security Awareness offers industry leading classes, tools and resources so that security awareness officers can easily and effectively manage their human cyber security risk. SANS Security Awareness has worked with nearly 2,000 organizations and trained eight million people around the world. Training content is translated into over 20 languages and built by the world's most knowledgeable cyber security experts. For additional details regarding SANS Security Awareness, please visit: http://securingthehuman.sans.org/u/s7N About NRI SecureTechnologies NRI SecureTechnologies is a leading Security Service Provider that was created August 1, 2000 as a subsidiary of Nomura Research Institute (NRI). Specializing in cyber security and recognized today as a leader in next-generation managed security services, security consulting and security software development. NRI Secure is focused is on delivering high-value security outcomes for clients with the precision and efficiency that define Japanese quality. (https://www.nri-secure.co.jp/service/learning/sans_sth.html) About SANS Institute The SANS Institute was established in 1989 as a cooperative research and education organization. SANS is the most trusted and, by far, the largest provider of cyber security training and certification to professionals at governments and commercial institutions world-wide. Renowned SANS instructors teach over 50 different courses at more than 200 live cyber security training events as well as online. GIAC, an affiliate of the SANS Institute, validates employee qualifications via 30 hands-on, technical certifications in information security. The SANS Technology Institute, a regionally accredited independent subsidiary, offers master's degrees in cyber security. SANS offers a myriad of free resources to the InfoSec community including consensus projects, research reports, and newsletters; it also operates the Internet's early warning system--the Internet Storm Center. At the heart of SANS are the many security practitioners, representing varied global organizations from corporations to universities, working together to help the entire information security community. (www.SANS.org) To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/sans-partners-with-nri-securetechnologies-to-help-japanese-businesses-manage-their-human-cyber-security-risk-300463570.html


MISSISSAUGA, ON, May 11, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI) a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities, today announced that at its 2017 Annual and Special Meeting of Shareholders held in Toronto, all nominees listed in the management proxy circular dated April 5, 2017 were elected as directors of the Company. The detailed results of the votes by proxy are as follows:


News Article | May 10, 2017
Site: www.prnewswire.com

"2017 is off to a very positive start," said John London, Nuvo's CEO.  "Our financial results were strong.  We made progress on our strategy of expanding and diversifying our revenue streams through the Russian regulatory approval of Pennsaid 2% and the license agreement with Sayre that will make Pennsaid 2% available in India, Sri Lanka, Bangladesh and Nepal. We continue to be pleased that we are running a profitable company, generating net positive cash flow and debt free." Nuvo is in active discussions relating to potential transactions to license or acquire additional, accretive commercial assets to further diversify the Company's product portfolio and maximize the Company's manufacturing capabilities at our GMP approved site in Varennes, Québec.  Nuvo is charting a course to build a business with product and geographic diversification. Nuvo is in a number of active discussions with potential commercial licensees of Pennsaid 2% for various global territories.  Nuvo anticipates signing licensing agreements covering multiple countries throughout 2017 and 2018.  Nuvo projects that incremental revenue from licensing agreements signed in 2017 will commence in 2018 and 2019, subject to obtaining regulatory approvals for Pennsaid 2% in the related territories. The 2016 Pennsaid 2% Trial was conducted in Germany and enrolled approximately 133 patients who had suffered a grade I or grade II ankle sprain as assessed by the investigator within 12 hours of injury.  Patients were randomly assigned on a double-blind basis to an active arm or a placebo arm and applied either Pennsaid 2% or a placebo consisting of a topical vehicle that includes all the constituent ingredients of Pennsaid 2%, except its active ingredient diclofenac sodium, to their injured ankle twice a day for 8 days.  The patients returned to the investigational site for in-depth evaluation on days 3, 5 and 8 of treatment.  The primary endpoint for the 2016 Pennsaid 2% Trial is reduction in pain on movement at day 3.  The 2016 Pennsaid 2% Trial will also measure a number of secondary endpoints including tenderness, ankle function, ankle swelling, overall assessment of benefit and satisfaction and use of rescue medication.  The 2016 Pennsaid 2% Trial commenced in November 2016 and was fully enrolled in March 2017.  Topline results for the 2016 Pennsaid 2% Trial are expected later in May 2017. Nuvo records revenue when it ships Pennsaid 2% commercial bottles and product samples to Horizon for Horizon's sale into the U.S. market.  The amount earned by Nuvo is based on a defined transfer price for each commercial bottle and product sample shipped to Horizon pursuant to its long-term, exclusive supply agreement with Horizon.  Nuvo's transfer price for Pennsaid 2% commercial bottles and product samples is not affected by Horizon's net selling price for prescriptions filled in the U.S.  Nuvo also receives contract service revenue from Horizon.  The timing of Nuvo shipments to Horizon do not necessarily align with when U.S. patients fill prescriptions written by their physicians. Horizon's orders from Nuvo are influenced by demand in the U.S. market, Horizon's inventory levels and management strategies.  On November 27, 2017, Federal Drug Supply Chain Security Act (DSCSA) rules come into force that require all manufacturers of drug products sold in the U.S. to serialize each individual package to enhance drug traceability in the event of an adverse event and to prevent drug counterfeiting.  In order to be in compliance with the DSCSA, also known as the Serialization Track and Trace Bill, the Company has purchased new packaging equipment and technology systems to individually serialize all Pennsaid 2% packaging.  In coordination with Horizon, the Company has planned to complete installation of this new equipment well before the November 27th implementation date of the DSCSA.  The new packaging equipment has arrived at the manufacturing plant in Varennes, Québec and the process of installing and qualifying it for commercial production has commenced.  It is expected that the new equipment with qualified software will be available to produce individually serialized commercial bottles in the second half of Q3. The U.S. Food and Drug Administration (FDA) was expected to publish regulations that grandfather existing non-serialized inventory in the supply chain as of November 27th, but has not released these much anticipated regulations yet.  Due to the uncertainty respecting how the rule will treat non-serialized inventory, Horizon has decided to draw down its existing Pennsaid 2% inventory of non-serialized product in advance of the November 27th implementation date.  Horizon has therefore advised Nuvo that it plans to defer any further commercial bottle production until the serialization equipment is operational.  Sample production is not affected by the serialization issue.  These anticipated production changes will have a negative impact on Nuvo's Q2 and Q3 sales and earnings relative to normal prescription trends and purchases by Horizon; however, it is expected that sales to Horizon will pick up in the remainder of the year, when the serialization equipment comes on stream and Horizon resumes its more typical ordering patterns, including rebuilding its inventory with serialized product to replace non-serialized inventory that it draws down. Table of Selected Financial Results For further details on the results, please refer to Nuvo's Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements which are available on the Company's website (www.nuvopharmaceuticals.com). Total revenue, consisting of product sales, royalties and contract and other revenue for the three months ended March 31, 2017 was $7.0 million compared to $7.8 million for the three months ended March 31, 2016.  The decrease in total revenue was primarily related to a decrease in product sales. Total operating expenses for the three months ended March 31, 2017 decreased to $4.7 million compared to $5.4 million for the three months ended March 31, 2016.  The decrease in operating expenses was primarily attributable to a decrease cost of goods sold (COGS) and general and administrative (G&A) expenses, slightly offset by an increase in research and development (R&D) expenses. COGS decreased to $2.8 million for the three months ended March 31, 2017 compared to $3.1 million for the three months ended March 31, 2016.  The decrease in COGS is attributable to a decrease in product sales.  The decrease in product sales during the current quarter reduced the gross margin on product sales to $3.9 million or 58% compared to $4.2 million or 57% in the comparative quarter. R&D expenses increased slightly to $0.3 million for the three months ended March 31, 2017 compared to $0.2 million for the three months ended March 31, 2016.  In the current quarter, the Company incurred R&D expenses related to the 2016 Pennsaid 2% Trial for the treatment of acute ankle sprains. G&A expenses decreased to $1.7 million for the three months ended March 31, 2017 compared to $2.1 million for the three months ended March 31, 2016.  In the current quarter, a $1.0 million decrease in stock-based compensation (SBC) expense was partially offset by an increase in regulatory consulting fees and an increase in general corporate costs due to the allocation of certain corporate G&A costs to Crescita in the comparative quarter. The Company earned net interest income of $38,000 for the three months ended March 31, 2017 compared to $56,000 for the three months ended March 31, 2016.  The decrease in net interest income in the current quarter related to the significantly lower cash balances as compared to the comparative period whereby $35.0 million was transferred to Crescita on March 1, 2016 as part of the reorganization transaction. The Company experienced a net foreign currency loss of $0.1 million for the three months ended March 31, 2017 compared to a net foreign currency loss of $0.5 million for the three months ended March 31, 2016. Net income from continuing operations was $2.2 million for the three months ended March 31, 2017 compared to $1.9 million for the three months ended March 31, 2016.  In the current quarter, the decrease in gross margin and a slight increase in R&D expenses were more than offset by a decrease in G&A expenses and a decrease in foreign exchange losses. Adjusted EBITDA decreased to $2.3 million for the three months ended March 31, 2017 compared to $3.0 million for the three months ended March 31, 2016.  In the current quarter, an increase in net income from continuing operations was more than offset by a decrease in SBC expenses. Cash and short-term investments were $18.6 million as at March 31, 2017 compared to $17.6 million as at December 31, 2016.  The $1.0 million increase in cash and short-term investments was primarily attributable to an increase in cash provided by operations. The number of common shares outstanding as at March 31, 2017 was 11,550,897. EBITDA is a non-IFRS financial measure.  The term EBITDA does not have any standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other companies.  The Company defines Adjusted EBITDA as net income from continuing operations before net interest income, plus income tax expense, depreciation, amortization and SBC.  Management believes Adjusted EBITDA is a useful supplemental measure from which to determine the Company's ability to generate cash available for working capital, capital expenditures and income taxes. The following is a summary of how EBITDA and Adjusted EBITDA are calculated: Management to Host Conference Call/Webcast Management will host a conference call to discuss the results tomorrow (Thursday, May 11, 2017) at 8:00 a.m. ET.  To participate in the conference call, please dial 1 (888) 231-8191 or (647) 427-7450, reference number 12423297.  Please call in 15 minutes prior to the call to secure a line.  You will be put on hold until the conference call begins. A taped replay of the conference call will be available two hours after the live conference call and will be accessible until May 18, 2017 by calling 1 (855) 859-2056 or (416) 849-0833, reference number 12423297. A live audio webcast of the conference call will be available through www.nuvopharmaceuticals.com.  Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast. About Nuvo Pharmaceuticals Inc. Nuvo (TSX:NRI) is a commercial healthcare company with a portfolio of commercial products and pharmaceutical manufacturing capabilities.  Nuvo has three commercial products that are available in a number of countries; Pennsaid 2%, Pennsaid and the heated lidocaine/tetracaine patch.  Pennsaid 2% is sold in the U.S. by Horizon Pharma plc (NASDAQ: HZNP) and is available for partnering in certain other territories around the world.  Nuvo manufactures Pennsaid for the global market and Pennsaid 2% for the U.S. market at its FDA, Health Canada and E.U. approved manufacturing facility in Varennes, Québec.  For additional information, please visit www.nuvopharmaceuticals.com. Forward-Looking Statements This Press Release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company's control. Nuvo's actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, readers should not rely on any of these forward-looking statements. Important factors that could cause Nuvo's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the risk factors included in Nuvo's most recent Annual Information Form dated March 1, 2017 under the heading "Risks Factors", and as described from time to time in the reports and disclosure documents filed by Nuvo with Canadian securities regulatory agencies and commissions. These and other factors should be considered carefully and readers should not place undue reliance on Nuvo's forward-looking statements. As a result of the foregoing and other factors, no assurance can be given as to any such future results, levels of activity or achievements and none of Nuvo or any other person assumes responsibility for the accuracy and completeness of these forward-looking statements. Any forward-looking statement made by the Company in this Press Release is based only on information currently available to it and speaks only as of the date on which it is made. Except as required by applicable securities laws, Nuvo undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.


LONDON, UK / ACCESSWIRE / February 16, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected stocks trading on the Toronto Exchange and belonging under the Drug Manufacturers industry. Companies recently under review include Nuvo Pharmaceuticals, Acerus Pharmaceuticals, and Avivagen. Get all of our free research reports by signing up at: On Wednesday, February 15, 2017, the Toronto Exchange Composite Index was up 0.37%, finishing the day at 15,844.95. The TSX Venture Composite Index, on the other hand, closed at 838.14, up 0.34%. Additionally, the Healthcare index was up by 3.22%, ending the session at 77.28. Active Wall St. has initiated research reports on the following equities: Nuvo Pharmaceuticals Inc. (TSX: NRI), Acerus Pharmaceuticals Corporation (TSX: ASP), and Avivagen Inc. (TSXV: VIV). Register with us now for your free membership and research reports at: On Wednesday, shares in Mississauga, Canada-based Nuvo Pharmaceuticals Inc. recorded a trading volume of 26,248 shares, which was higher than their three months' average volume of 11,539 shares. The stock ended the day 1.60% lower at $5.54. Nuvo Pharma's stock has advanced 1.47% in the last one month and 12.80% in the previous one year. The Company's shares are trading above its 50-day moving average. The stock's 200-day moving average of $6.31 is above its 50-day moving average of $5.51. Shares of the Company, which operates as a life sciences company, are trading at PE ratio of 1,108.00. See our research report on NRI.TO at: Mississauga, Canada headquartered Acerus Pharmaceuticals Corp.'s stock finished Wednesday's session flat at $0.13 with a total volume of 462,169 shares traded. Over the last one month and the previous three months, Acerus Pharma's shares have rallied 6,971.43% and 7,515.38%, respectively. Furthermore, the stock has rallied 2,202.33% in the past one year. The Company's shares are trading below its 50-day and 200-day moving averages. Acerus Pharma' 50-day moving average of $1.29 is above its 200-day moving average of $0.44. Shares of the Company, which focuses on developing, manufacturing, marketing, and distributing pharmaceutical products for male hypogonadism, women's hormone replacement therapy, and female sexual dysfunction in Canada, are trading at a PE ratio of 9.29. The complimentary research report on ASP.TO at: Ottawa, Canada headquartered Avivagen Inc.'s stock closed the day 4.55% lower at $0.10. The stock recorded a trading volume of 510,000 shares, which was above its three months' average volume of 372,163 shares. Shares of the company, which develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal's own health defenses, are trading below their 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $0.15 is greater than its 50-day moving average of $0.12. Get free access to your research report on VIV.V at: Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | March 1, 2017
Site: www.prnewswire.com

- Reports 32% Year-Over-Year Revenue Growth - - Nuvo to Host Conference Call/Audio Webcast March 2 at 8:00 a.m. ET - MISSISSAUGA, ON, March 1, 2017 /PRNewswire/ - Nuvo Pharmaceuticals Inc. (Nuvo or the Company) (TSX:NRI), a commercial healthcare company with a portfolio of...


NEW YORK, NY / ACCESSWIRE / February 15, 2017 / Nomura Research Institute (OTC PINK: NRILY), a leading provider of consulting services and system solutions, today announced its Valuable OTC Products and Liquidity Control System (VOLCS) has been awarded the Best Utilities Technology at the 2017 Fund Technology and WSL Awards. NRI's VOLCS offering provides a multipurpose management system for financial institutions, specifically establishing strong due-date management for structured bonds and OTC derivatives and cash management. While designed for financial institutions, the solution can also be separated and utilized individually by non-financial firms. Most recently, structured bonds and OTC derivatives have been receiving more attention due to the effects of stock price changes and Japan's negative interest rates. Both financial products are complicated and require detailed calculation and settlement day management, causing a major operational and financial burden to financial institutions. VOLCS enables its users to reduce the operational burden significantly, resulting in increased trading volume, as well as provides the option to reallocate their resources from due day management to strategic division for more sales power. A couple of major financial institutions have already adopted VOLCS since its launch in June of 2016. "Financial institutions across the globe are looking to drive efficiencies in their day-to-day operations with innovative technologies to lower their cost burden, ease management challenges and increase their bottom line," said Minoru Yokote, Senior Managing Director of NRI. "NRI is committed to distributing our system solutions and consulting services that are industry-leading in Japan across the global marketplace to address these key challenges, and it is an honor to be recognized for our contribution." The Fund Technology and WSL Awards recognize technology solution and providers catering to asset managers and institutional traders that have demonstrated exceptional customer service and innovative product development over the past year. 2017's event has been expanded to recognize the efforts of technology providers, data specialists and exchanges meeting the needs of the wider asset management community, particularly mutual funds. Founded in 1965, NRI is a leading global provider of system solutions and consulting services with annual sales above $3.7 billion. NRI offers clients holistic support of all aspects of operations from back- to front-office, with NRI's research expertise and innovative solutions as well as understanding of operational challenges faced by financial services firms. The clients include broker-dealers, asset managers, banks and insurance providers. NRI has 35 offices globally including New York, London, Tokyo, Hong Kong and Singapore, and over 10,000 employees.


Valuable OTC Products and Liquidity Control System (VOLCS) has been awarded the Best Utilities Technology at the 2017 Fund Technology and WSL Awards. NRI's VOLCS offering provides a multipurpose management system for financial institutions, specifically establishing strong due-date management for structured bonds and OTC derivatives and cash management. While designed for financial institutions, the solution can also be separated and utilized individually by non-financial firms. Most recently, structured bonds and OTC derivatives have been receiving more attention due to the effects of stock price changes and Japan's negative interest rates. Both financial products are complicated and require detailed calculation and settlement day management, causing a major operational and financial burden to financial institutions. VOLCS enables its users to reduce the operational burden significantly, resulting in increased trading volume, as well as provides the option to reallocate their resources from due day management to strategic division for more sales power. A couple of major financial institutions have already adopted VOLCS since its launch in June of 2016. "Financial institutions across the globe are looking to drive efficiencies in their day-to-day operations with innovative technologies to lower their cost burden, ease management challenges and increase their bottom line," said Minoru Yokote, Senior Managing Director of NRI. "NRI is committed to distributing our system solutions and consulting services that are industry-leading in Japan across the global marketplace to address these key challenges, and it is an honor to be recognized for our contribution." The Fund Technology and WSL Awards recognize technology solution and providers catering to asset managers and institutional traders that have demonstrated exceptional customer service and innovative product development over the past year. 2017's event has been expanded to recognize the efforts of technology providers, data specialists and exchanges meeting the needs of the wider asset management community, particularly mutual funds. Founded in 1965, NRI is a leading global provider of system solutions and consulting services with annual sales above $3.7 billion. NRI offers clients holistic support of all aspects of operations from back- to front-office, with NRI's research expertise and innovative solutions as well as understanding of operational challenges faced by financial services firms. The clients include broker-dealers, asset managers, banks and insurance providers. NRI has 35 offices globally including New York, London, Tokyo, Hong Kong and Singapore, and over 10,000 employees.

Loading NRI collaborators
Loading NRI collaborators